Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $42,500.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 5,000 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $8.50, for a total value of $42,500.00. Following the completion of the sale, the insider directly owned 1,361,053 shares in the company, valued at $11,568,950.50. This represents a 0.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.52, for a total value of $235,152.00.
• On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total transaction of $147,900.00.

Xeris Biopharma Stock Up 3.2%

Shares of NASDAQ:XERS opened at $8.60 on Friday. The firm’s 50 day moving average price is $7.91 and its 200 day moving average price is $6.83. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -78.18 and a beta of 0.66. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $5.25 and a fifty-two week high of $10.08. The company has a quick ratio of 1.50, a current ratio of 1.45 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%.The firm had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. As a group, equities research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Xeris Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC purchased a new position in Xeris Biopharma in the fourth quarter valued at approximately $25,000. KBC Group NV acquired a new stake in Xeris Biopharma during the first quarter worth approximately $27,000. Allworth Financial LP purchased a new stake in shares of Xeris Biopharma during the 2nd quarter worth approximately $34,000. State of Wyoming purchased a new stake in shares of Xeris Biopharma during the 2nd quarter worth approximately $52,000. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in shares of Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after buying an additional 7,421 shares in the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

XERS has been the subject of a number of analyst reports. Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday. Wall Street Zen lowered Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.